{"analyses":[{"groupIds":["OG000"],"nonInferiorityComment":"P\\<0.005 was considered statistically significant while 0.005 \\<P\\<0.05 was considered evidence of a strong trend.","nonInferiorityType":"OTHER","pValue":"0.56","statisticalMethod":"Wilcoxon signed rank test"},{"groupIds":["OG001"],"nonInferiorityComment":"P\\<0.005 was considered statistically significant while 0.005 \\<P\\<0.05 was considered evidence of a strong trend.","nonInferiorityType":"OTHER","pValue":"0.65","statisticalMethod":"Wilcoxon signed rank test"},{"groupIds":["OG002"],"nonInferiorityComment":"P\\<0.005 was considered statistically significant while 0.005 \\<P\\<0.05 was considered evidence of a strong trend.","nonInferiorityType":"OTHER","pValue":"0.56","statisticalMethod":"Wilcoxon signed rank test"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0","upperLimit":"0","value":"0"},{"groupId":"OG001","lowerLimit":"0","upperLimit":"0","value":"0"},{"groupId":"OG002","lowerLimit":"0","upperLimit":"0","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"28"},{"groupId":"OG002","value":"28"}],"units":"Participants"}],"description":"HIV viral load in peripheral blood mononuclear cells was assessed by quantitative real-time polymerase chain reaction (PCR). The lower limit of detection for HIV viral load is \\<50 copies mL.","dispersionType":"Inter-Quartile Range","groups":[{"description":"Baseline to 4 weeks for participants treated with pomalidomide 5 mg by mouth (p.o.) for 21 of 28 days.","id":"OG000","title":"Baseline to 4 Weeks"},{"description":"Baseline to 8 weeks for participants treated with pomalidomide 5 mg by mouth (p.o.) for 21 of 28 days.","id":"OG001","title":"Baseline to 8 Weeks"},{"description":"Baseline to end of treatment for participants treated with pomalidomide 5 mg by mouth (p.o.) for 21 of 28 days.","id":"OG002","title":"Baseline to End of Treatment"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"Baseline to 4 weeks, baseline to 8 weeks and baseline to end of treatment","title":"Human Immunodeficiency Virus (HIV) Viral Load","type":"SECONDARY","unitOfMeasure":"Copies/mL"}